title: Effects of ramosetron oral disintegrating tablets on gastric emptying: crossover study using the 13C-acetic acid breath test.
abstract: OBJECTIVE
  Ramosetron is a new selective 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist that reportedly has more potent antiemetic effects than other 5-HT3 receptor antagonists. The aim of this study was to determine the effect of ramosetron pretreatment on gastric emptying using the 13C-acetic acid breath test.
  
  
  METHODS
  Ten healthy male and female volunteers participated in this randomized, twoway crossover study. After they had fasted overnight, the subjects were randomly assigned to receive 0.1 mg ramosetron 1 hour before ingestion of a test meal (200 kcal per 200 mL, containing 100 mg 13C acetate) or to receive the test meal alone. Under both conditions, breath samples were collected for 150 min following ingestion of the meal. Statistical comparison of the parameters between the two test conditions was performed.
  
  
  RESULTS
  No significant differences in the calculated parameters, including T 1/2, T lag, GEC or β and κ, were observed between the two test conditions.
  
  
  CONCLUSIONS
  The present study revealed that 0.1 mg ramosetron had no significant effect on the rate of gastric emptying. Thus, our results suggest that ramosetron can be administered safely, without gastrointestinal adverse effects, even to terminal cancer patients with delayed or accelerated gastric emptying abnormality.
authors.forename: Akihiko
authors.initials: A
authors.lastname: Kusakabe
authors.forename: Takashi
authors.initials: T
authors.lastname: Nonaka
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Sekino
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iida
authors.forename: Hiroki
authors.initials: H
authors.lastname: Endo
authors.forename: Tomoko
authors.initials: T
authors.lastname: Koide
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Takahashi
authors.forename: Koji
authors.initials: K
authors.lastname: Fujita
authors.forename: Masato
authors.initials: M
authors.lastname: Yoneda
authors.forename: Ayumu
authors.initials: A
authors.lastname: Goto
authors.forename: Eiji
authors.initials: E
authors.lastname: Gotoh
authors.forename: Shin
authors.initials: S
authors.lastname: Maeda
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
authors.forename: Chihiro
authors.initials: C
authors.lastname: Nosaka
authors.forename: Masahiko
authors.initials: M
authors.lastname: Inamori
mesh_terms: D019342:Acetic Acid; D000284:Administration, Oral; D000328:Adult; D000932:Antiemetics / Q000008:administration & dosage* / Q000737:chemistry; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000737:chemistry; D001944:Breath Tests; D002247:Carbon Isotopes; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D006801:Humans; D007564:Japan; D008297:Male; D019518:Postprandial Period; D011237:Predictive Value of Tests; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000008:administration & dosage* / Q000737:chemistry; D012995:Solubility; D013607:Tablets; D013997:Time Factors; D055815:Young Adult
chemical_list: D000932:Antiemetics; D001562:Benzimidazoles; D002247:Carbon Isotopes; D058831:Serotonin 5-HT3 Receptor Antagonists; D013607:Tablets; C071315:ramosetron; D019342:Acetic Acid